Tiansheng Pharmaceutical Group Co Ltd (002872) — Cash Flow-to-Debt Ratio
Tiansheng Pharmaceutical Group Co Ltd (002872) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of CN¥-22.57 Million could theoretically repay 0% of its total liabilities (CN¥679.17 Million) in one year. See cash generation quality of Tiansheng Pharmaceutical Group Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tiansheng Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Tiansheng Pharmaceutical Group Co Ltd across 13 annual periods. Also explore 002872 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Tiansheng Pharmaceutical Group Co Ltd (2012–2024)
Year-by-year debt coverage analysis for Tiansheng Pharmaceutical Group Co Ltd. For market capitalisation and broader financial context, see 002872 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.07x | CN¥50.15 Million | CN¥721.80 Million | ▲ +302.3% |
| 2023 | -0.03x | CN¥-24.56 Million | CN¥715.25 Million | ▼ -130.1% |
| 2022 | 0.11x | CN¥89.18 Million | CN¥782.23 Million | ▲ +405.3% |
| 2021 | 0.02x | CN¥18.97 Million | CN¥840.79 Million | ▼ -85.1% |
| 2020 | 0.15x | CN¥189.75 Million | CN¥1.26 Billion | ▲ +50.5% |
| 2019 | 0.10x | CN¥144.21 Million | CN¥1.44 Billion | ▼ -2.8% |
| 2018 | 0.10x | CN¥153.99 Million | CN¥1.49 Billion | ▲ +425.3% |
| 2017 | -0.03x | CN¥-55.75 Million | CN¥1.76 Billion | ▼ -109.6% |
| 2016 | 0.33x | CN¥506.68 Million | CN¥1.53 Billion | ▲ +91.5% |
| 2015 | 0.17x | CN¥213.54 Million | CN¥1.24 Billion | ▼ -4.3% |
| 2014 | 0.18x | CN¥191.99 Million | CN¥1.06 Billion | ▲ +241.9% |
| 2013 | 0.05x | CN¥57.06 Million | CN¥1.08 Billion | ▼ -71.2% |
| 2012 | 0.18x | CN¥145.06 Million | CN¥792.28 Million | — |